is a vaccine intended to provide acquired immunity against severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus that causes coronavirus disease 2019 (COVID‑19).
European Medicines Agency has published Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7-10 March 2022.
COVID-19 Vaccine Janssen: small vessel vasculitis added as...
Demand for the COVID-19 vaccine produced by U.S. biotech firm Novavax has been underwhelming in the European Union's main countries in the early rollout,...
A drug once hailed as Japan's biggest contribution in the global fight against COVID-19 suffered another setback, as Fujifilm Holdings Corp said it was...
Johnson & Johnson announced the completion of a landmark agreement between Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson,...
Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that with the assistance of the U.S. Government, it has...